JUBLPHARMA - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 4.0

📈 Jubilant Pharmova Ltd (JUBLPHARMA) Swing Trade Analysis

JUBLPHARMA is showing signs of technical stabilization after a recent pullback, supported by strong institutional buying and a favorable MACD crossover. While valuation is high, the stock is approaching a potential rebound zone, making it a decent swing trade candidate.

✅ Strengths

Technical Setup

MACD: 9.31 — bullish momentum

Price above 200 DMA (₹1,021) and near 50 DMA (₹1,138) — consolidation zone

Volume spike — current volume nearly 3× weekly average

Institutional Interest

FII holding up by 0.17%

DII holding surged by 2.47% — strong domestic support

Fundamentals

EPS: ₹28.9 — solid earnings

Debt-to-equity: 0.44 — manageable leverage

Book Value: ₹393 — price-to-book ratio ~2.9, reasonable for pharma

⚠️ Risks

Valuation

P/E of 38.1 vs industry average of 34.0 — slightly overvalued

PEG Ratio: 3.75 — suggests expensive relative to growth

Profit Decline

PAT dropped from ₹153 Cr. to ₹102 Cr. — 3.83% quarterly decline

Momentum Indicators

RSI: 44.5 — neutral, not yet bullish

Price below recent high of ₹1,310 — resistance zone ahead

Dividend Yield: Low at 0.43%

🎯 Optimal Entry Price

Entry Zone: ₹1,135–₹1,145

Near 50 DMA and recent support

Confirm entry with bullish candle and volume above ₹1,150

🚪 Exit Strategy (If Already Holding)

Short-Term Target: ₹1,210–₹1,245

Based on resistance zones and Fibonacci retracement levels

Stop Loss: ₹1,095

Below recent swing low and psychological ₹1,100 level

📌 Summary

JUBLPHARMA is a moderately strong swing candidate with improving technicals and institutional support. Entry near ₹1,135–₹1,145 offers a tactical setup with targets around ₹1,245. If already holding, consider exiting near ₹1,210–₹1,245 or trail stop loss to ₹1,095.

Would you like to compare this with other pharma stocks like Divi’s Labs or Cipla for sector rotation?

Edit in a page